Literature DB >> 3874835

Characterization of human tumor necrosis factor produced by peripheral blood monocytes and its separation from lymphotoxin.

H C Kelker, J D Oppenheim, D Stone-Wolff, D Henriksen-DeStefano, B B Aggarwal, H C Stevenson, J Vilcek.   

Abstract

Cultures of human peripheral blood leukocytes (PBL) induced with phytohemagglutinin (PHA) and the phorbol ester 12-0-tetradecanoylphorbol 13-acetate (TPA) produced two types of cytotoxic proteins, indistinguishable in the in vitro assay employing murine L 929 cells as targets. One of these proteins had the antigenic and physicochemical properties of lymphotoxin (LT). We have identified the other cytotoxin as tumor necrosis factor (TNF), mainly on the basis of antigenic cross-reactivity demonstrated with antiserum to TNF, and also by its characteristic physicochemical properties and cell source. Unlike LT, PBL-derived TNF did not bind to Concanavalin A-Sepharose or to several other agglutinin-Sepharose columns specific for carbohydrate moieties common in glycoproteins. The molecular weight of native TNF determined by gel filtration was approximately 40,000 while SDS-PAGE revealed a single sharp peak of 16,500 +/- 500. When cultures of monocytes and lymphocytes separated by elutriation were stimulated with PHA and/or TPA, monocytes were the major source of TNF. In contrast, only lymphocytes produced LT. A mixture of antisera to TNF and LF neutralized all cytotoxicity of crude human lymphokine preparations for L 929 cells, suggesting that TNF and LT are either the only, or the major, cytotoxic proteins present in such crude lymphokine preparations demonstrable in this assay.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3874835     DOI: 10.1002/ijc.2910360112

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  24 in total

Review 1.  Regulation of tumor necrosis factor production by monocyte-macrophages and lymphocytes.

Authors:  G Trinchieri
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

Review 2.  Resistance of tumor cells to tumor necrosis factor.

Authors:  H M Shepard; G D Lewis
Journal:  J Clin Immunol       Date:  1988-09       Impact factor: 8.317

Review 3.  Linking the microbiota and metabolic disease with lymphotoxin.

Authors:  Vaibhav Upadhyay; Yang-Xin Fu
Journal:  Int Immunol       Date:  2013-05-08       Impact factor: 4.823

4.  Identity of human B-cell line cytotoxic lymphokine with tumor necrosis factor type beta.

Authors:  H I Yamanaka; A Karpas
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

Review 5.  Lymphotoxin organizes contributions to host defense and metabolic illness from innate lymphoid cells.

Authors:  Vaibhav Upadhyay; Yang-Xin Fu
Journal:  Cytokine Growth Factor Rev       Date:  2013-12-24       Impact factor: 7.638

Review 6.  Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.

Authors:  Bharat B Aggarwal; Subash C Gupta; Ji Hye Kim
Journal:  Blood       Date:  2011-11-03       Impact factor: 22.113

7.  The effect of pentoxifylline on the healing of intestinal anastomosis in rats with experimental obstructive jaundice.

Authors:  M Cömert; F Taneri; E Tekin; E Ersoy; S Oktemer; E Onuk; E Düzgün; F Ayoğlu
Journal:  Surg Today       Date:  2000       Impact factor: 2.549

8.  Sendai virus induces high levels of tumor necrosis factor mRNA in human peripheral blood leukocytes.

Authors:  S L Berent; R M Torczynski; A P Bollon
Journal:  Nucleic Acids Res       Date:  1986-11-25       Impact factor: 16.971

9.  Increased production of tumor necrosis factor and prostaglandin E2 by monocytes in cancer patients and its unique modulation by their plasma.

Authors:  K Nara; H Odagiri; M Fujii; Y Yamanaka; M Yokoyama; T Morita; M Sasaki; M Kon; T Abo
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

10.  Pulmonary inflammation and fibrosis in a murine model of asbestosis and silicosis. Possible role of tumor necrosis factor.

Authors:  E Bissonnette; M Rola-Pleszczynski
Journal:  Inflammation       Date:  1989-06       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.